News

July 10, 2015 10:30 am
Dr. Ola Landgren announced the opening of a new Phase I/II clinical trial at Memorial Sloan-Kettering Cancer Center for patients with relapsed and/or refractory myeloma. The trial will test a new proteasome inhibitor called VLX1570, which is given...
June 28, 2015 10:30 am
The IMF will host a two-day Patient & Family Seminar August 21-22 at the Sheraton Universal Hotel in Los Angeles, California. What do you get at an IMF Patient & Family Seminar? Attendees will receive the latest information on myeloma,...
June 28, 2015 10:30 am
Myeloma patients need to have access to their medical records. But gathering years of data from dozens of different providers can be a challenge. At this summer’s annual Support Group Leader Summit, the IMF will present an educational session...
June 27, 2015 10:30 am
On June 26, the Committee for Medicinal Products for Human Use (CHMP), an advisory committee of the European Medicines Agency (EMA), released a positive opinion regarding European approval of Farydak® (panobinostat) for the treatment of myeloma in...

Pages